ERBB2 and lung adenocarcinoma: As far as we know, this study is the first study to compare the efficacy of pemetrexed-based chemotherapy between HER2-mutant and groups of EGFR-mutant, ALK/ROS1-rearranged and KRAS-mutant lung adenocarcinoma.